Keskmine (tavaline)

Ravimiuuringud 2013

dr Kaire Aadamsoo
  • Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety of SPD489 in Combination with an Antidepressant in the Treatment of Adults with Major Depressive Disorder with Inadequate Response to Prospective Treatment with an Antidepressant. (protokoll SPD489-323).
  • A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with schizophrenia (protokoll 14724A).
  • A Phase 3, Open-label, Multicenter, 12-month Extension Safety and Tolerability Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Residual Symptoms or Inadequate Response Following Treatment With an Antidepressant. Protokoll SPD489-329
  • Interventional, open-label, flexible-dose extension study of aripiprazole once-monthly in patients with schizophrenia (protokoll 14724B).
dr Anu Ambos
  • A randomized, open-label, active-controlled, 3-arm parallel-group, 26-week study comparing the efficacy and safety of lixisenatide to that of insulin glulisine once daily and insulin glulisine three times daily in patients with Type 2 diabetes insufficiently controlled with insulin glargine with or without metformin. (protokoll EFC12626).
dr Evelin Eding
  • Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia (protokoll 14644A).
  • Interventional, open-label, flexible-dose extension study of brexpiprazole in patients with schizophrenia (protokoll 14644B).
dr Ülo Kallassalu
  • Efficacy and safety of tianeptine oral administration (25 to 50 mg/day) in eldery patients suffering from Major Depressive Disoder. A 8-week, randomized, double-blind,  flexible-dose, parallel groups, placebo-controlled, international, multicentre study with escitalopram as active control, followed by an optional double-blind extension treatment period of 16 weeks (protokoll CL3-01574-237).
dr Kersti Kukk
  • Phase II placebo-controlled study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) delivered IM followed by electroporation (EP) with CELLECTRA®-5P for the treatment of biopsy-proven CIN 2/3 or CIN 3 with dokumented HPV 16 or 18 (protokoll HPV-003).
dr Leonhard Kukk
  • A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F ± GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic, Castrate-Resistant Prostate Cancer (protokoll BNIT-PRV-301).
dr Riina Kütner
  • A multicenter, open-label, single-arm study of pertuzumab in combination with trastuzumab and a taxane in first line treatment of patients with HER2-positive advanced (metastatic or locally recurrent) breast cancer (protokoll MO28047).
dr Ande Lindemäe
  • A fixed dose, dose response study for ropinirole prolonged release (PR) in patients with early stage Parkinson Disease (protokoll ROP111662).
dr Diana Loigom
  • A pilot, exploratory, randomized, phase 2 safety study evaluating tumor cell (plasma cell) mobilization and apheresis product contamination in plerixafor plus non-pegylated G-CSF mobilized patients and in non-pegylated G-CSF alone mobilized patients (protokoll ARD12858).
dr Merike Luman
  • A Multicenter, Multiple-Dose, Two-arm, Active-Controlled, Double-Blind, Double-Dummy Study to Compare the Therapeutic Efficacy and Safety of Oral Doses of Cinacalcet HCI With Intravenous Doses of AMG 416 in Hemodialysis Subjects With Secondary Hyperparathyroidism (protokoll 20130360).

dr Toomas Marandi
  • A randomized, open-label, multi-center, active-controlled, parallel group study to determine the efficacy and safety of the REG1 anticoagulation system compared to bivalirudin in patients undergoing Percutaneous Coronary Intervention (protokoll REG1-CLIN310)
dr Mari Meren
  • A 52-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group, active controlled study to compare the effect of QVA149 (indacaterol maleate/ glycopyrronium bromide) with salmeterol/fluticasone on the rate of exacerbations in subjects with moderate to very severe COPD. (protokoll CQVA149A2318).
dr Pille Mukk
  • A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents. Protokoll  MK-5592-069.
dr Ene Ojassalu
  • A randomized, double-blind, double-dummy study assessing the safety and tolerability of sarilumab and tocilizumab in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF antagonists. Protokoll SFY13370
  • Physical activity in patients with rheumatoid arthritis treated with adalimumab in routine clinical practice (protokoll P13-683)
dr Anneli Parksepp
  • Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose long-term study to evaluate the maintenance of efficacy and safety of 1 to 3 mg/day of brexpiprazole as adjunctive treatment in patients with major depressive disorder with an inadequate response to antidepressant treatment (protokoll 14570A)
  • Interventional, randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study to evaluate the efficacy and safety of brexpiprazole (1 and 3 mg/day) as adjunctive treatment in elderly patients with major depressive disorder with an inadequate response to antidepressant treatment (protokoll 14571A).
dr Kristi Pender
  • A randomized, double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar etanercept (GP2015) and Enbrel® in patients with moderate to severe chronic plaque-type psoriasis (protokoll GP15-302).
dr Helis Pokker
  • A multicenter, single arm study of trastuzumab emtansine (T-DM1) in HER2 positive locally advanced or metastatic breast cancer patients who have received prior anti-HER2 and chemotherapy-based treatment (protokoll MO28231.
  • A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients with Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib (protokoll VEG115232).
dr Kadri Putnik
  • A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically Resected, Cutaneous BRAF-Mutant Melanoma at High Risk for Recurrence (BRIM8) (protokoll GO27826).


dr Pentti Põder
  • Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering from Acute Decompensated Heart Failure [TRUE-AHF] (protokoll ULA01)
dr Eevi Pärsik
  • A Prospective Observational Study to Evaluate the Relationship between Disease State and Change in Quality of Life in Ancylosing Spondylitis Patients treated with Remicade® (infliximab) or Simponi® (golimumab) (protokoll MK 2155-194).
dr Eve Raussi
  • An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GKS2586184 in patients with mild to moderate systemic lupus erythematosus (protokoll JAK115919.
  • A multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis (protokoll I1F-MC-RHAP(a)).
dr Siim Schneider
  • A randomized, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke (protokoll 12649A).
dr Jüri Teras
  • A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections (protokoll TP-434-008).
dr Tõnu Vanakesa
  • A double blind, randomized, placebo controlled phase II study to assess the efficacy of recPRAME +AS15 Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected PRAME-positive, Non-Small Cell Lung Cancer (protokoll 116389).
dr Margus Viigimaa
  • A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome (protokoll EFC11570).